BDBM320258 N-(2-carboxyindol-5-yl)-2-(4-(5-chloro-2-(1H-tetrazol-1-yl)phenyl))-2-oxo-pyridin-1-yl)acetamide ::US10174020, Compound 6
SMILES: CC(C)(C)OC(=O)c1cc2cc(NC(=O)Cn3ccc(cc3=O)-c3cc(Cl)ccc3-n3cnnn3)ccc2[nH]1
InChI Key: InChIKey=FYJMLBSKCKPKGN-UHFFFAOYSA-N
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coagulation factor XI (Homo sapiens (Human)) | BDBM320258 (N-(2-carboxyindol-5-yl)-2-(4-(5-chloro-2-(1H-tetra...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 14 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
SICHUAN HAISCO PHARMACEUTICAL CO., LTD. US Patent | Assay Description The following method was used to test the in vitro inhibitory effect of the compounds of the present invention on the activity of human blood-coagula... | US Patent US10174020 (2019) BindingDB Entry DOI: 10.7270/Q2BK1FGM | |||||||||||
More data for this Ligand-Target Pair |